Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Next Previous
X
Search
Trial Profile

A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 800 TCR (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 27 Jan 2024 Results (n=19) investigating T cells transduced with a TCR targeting HERV-E (HERV-E T cells) for the treatment of mccRCC presented at the 2024 Genitourinary Cancers Symposium
    • 09 Nov 2023 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2023 Results (n=11) assessing the safety of adoptively infused HERV-E TCR in mccRCC pts presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top